Taltz

RSS

ixekizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Taltz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Taltz.

For practical information about using Taltz, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 11/05/2022

Authorisation details

Product details
Name
Taltz
Agency product number
EMEA/H/C/003943
Active substance
ixekizumab
International non-proprietary name (INN) or common name
ixekizumab
Therapeutic area (MeSH)
Psoriasis
Anatomical therapeutic chemical (ATC) code
L04AC
Publication details
Marketing-authorisation holder
Eli Lilly and Company (Ireland) Limited
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
25/04/2016
Contact address

Dunderrow
Kinsale
Co. Cork
Ireland

Product information

16/12/2021 Taltz - EMEA/H/C/003943 - II/0045/G

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Plaque psoriasis

Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Psoriatic arthritis

Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating
3 ratings